-
Mashup Score: 21Fauxcoll gradient - 11 day(s) ago
Fauxcoll gradient, Blood, Volume 115, Issue 13, 1 April 2010, Pages 2567, https://doi.org/10.1182/blood-2010-03-272575
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4My top artist of 2024 - Listen now - 1 month(s) ago
2024 Wrapped
Source: open.spotify.comCategories: General Medicine News, Hem/OncsTweet-
Unsurprisingly !#SpotifyWrapped https://t.co/1E7rbROlgp https://t.co/3BzmBBxrqk
-
-
Mashup Score: 69Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs) - 1 month(s) ago
Key Points. Disease type, baseline cytopenia, lymphodepletion intensity, and systemic inflammation were strongly associated with severe early ICAHT.We vali
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Very excited to share our work led by @emilyliangmd just published in @BloodAdvances! https://t.co/m1v1U3bWGI We used the {tidymodels} framework in R to develop models (eIPM) predictive of hematotoxicity in CAR T-cell therapy recipients. Models performed well in our independentā¦ https://t.co/ygu0Ggl2Z0 https://t.co/mR481iRXaZ https://t.co/dFVv2Tl8iR
-
-
Mashup Score: 69Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs) - 1 month(s) ago
Key Points. Disease type, baseline cytopenia, lymphodepletion intensity, and systemic inflammation were strongly associated with severe early ICAHT.We vali
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Very excited to share our work led by @emilyliangmd just published in @BloodAdvances! https://t.co/m1v1U3bWGI We used the {tidymodels} framework in R to develop models (eIPM) predictive of hematotoxicity in CAR T-cell therapy recipients. Models performed well in our independentā¦ https://t.co/ygu0Ggl2Z0 https://t.co/mR481iRXaZ https://t.co/dFVv2Tl8iR
-
-
Mashup Score: 69Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs) - 1 month(s) ago
Key Points. Disease type, baseline cytopenia, lymphodepletion intensity, and systemic inflammation were strongly associated with severe early ICAHT.We vali
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Very excited to share our work led by @emilyliangmd just published in @BloodAdvances! https://t.co/m1v1U3bWGI We used the {tidymodels} framework in R to develop models (eIPM) predictive of hematotoxicity in CAR T-cell therapy recipients. Models performed well in our independentā¦ https://t.co/ygu0Ggl2Z0 https://t.co/mR481iRXaZ https://t.co/dFVv2Tl8iR
-
-
Mashup Score: 19
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Exciting to hear the Korean experience with CAR T-cell therapy from Samsung Medical Center in Seoul from Dr. Seok Jin Kim! Looking forward to see updated results with anbal-cel https://t.co/jALYCVQC1K #ICBMT24 @ICBMT_Korea https://t.co/9NuPZRtRbI
-
-
Mashup Score: 5Hindsight Bias - The Decision Lab - 5 month(s) ago
Hindsight bias, or the knew-it-all-along, is the tendency to claim currents events were to happen even though it was completely unpredictable in the past.
Source: thedecisionlab.comCategories: General Medicine News, Hem/OncsTweet-
Reflecting on two pernicious cognitive biases often happening during clinical care: - Hindsight bias ("knew-it-all-along" effect) https://t.co/rHuGkVDIwh - Self-serving bias: when we attribute positive events and successes to our own character or actions, while we blame negativeā¦ https://t.co/QZqute0pzH
-
-
Mashup Score: 117CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study - 6 month(s) ago
This trial identifies CD22 as an immunotherapeutic target in large B-cell lymphoma and demonstrates the durable clinical activity of CAR22 in patients with disease progression after CAR19 therapy. Although these findings are promising, it is essential to recognise that this is a phase 1 dose-finding study. Further investigations are warranted to establish the long-term efficacy and to delineate the patient subgroups that will derive the most benefit from this therapeutic approach.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Fresh off the press, exciting results from Frank et al @StanfordMed CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study https://t.co/q6u0mm6SGo Looking forward to the multicenter phase 2ā¦ https://t.co/2z3lzcdwzI
-
-
Mashup Score: 118CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study - 6 month(s) ago
This trial identifies CD22 as an immunotherapeutic target in large B-cell lymphoma and demonstrates the durable clinical activity of CAR22 in patients with disease progression after CAR19 therapy. Although these findings are promising, it is essential to recognise that this is a phase 1 dose-finding study. Further investigations are warranted to establish the long-term efficacy and to delineate the patient subgroups that will derive the most benefit from this therapeutic approach.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Fresh off the press, exciting results from Frank et al @StanfordMed CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study https://t.co/q6u0mm6SGo Looking forward to the multicenter phase 2ā¦ https://t.co/2z3lzcdwzI
-
-
Mashup Score: 115CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study - 6 month(s) ago
This trial identifies CD22 as an immunotherapeutic target in large B-cell lymphoma and demonstrates the durable clinical activity of CAR22 in patients with disease progression after CAR19 therapy. Although these findings are promising, it is essential to recognise that this is a phase 1 dose-finding study. Further investigations are warranted to establish the long-term efficacy and to delineate the patient subgroups that will derive the most benefit from this therapeutic approach.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Fresh off the press, exciting results from Frank et al @StanfordMed CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study https://t.co/q6u0mm6SGo Looking forward to the multicenter phase 2ā¦ https://t.co/2z3lzcdwzI
-
That one time @BloodJournal published a facetious cocktail recipe. šøš©ø "The result, shown in the figure, is sweet and fruity, may be chilled if desired, and is best enjoyed with a hematologist." https://t.co/aYQXr6hvXD https://t.co/AdTxxHpbZU